DUROM ACETABULAR COMPONENT 56/50 CODE P
Report
- Report Number
- 9613350-2014-03425
- Event Type
- Injury
- Date Received
- April 7, 2014
- Date of Event
- February 12, 2014
- Report Date
- March 10, 2014
- Manufacturer
- ZIMMER GMBH
- Product Code
- KWA
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GM
- Reporter Occupation
- PHYSICIAN
Narratives
THE MANUFACTURER DID NOT RECEIVE DEVICES OR X-RAYS FOR REVIEW. OTHER SOURCE DOCUMENT (USER REPORT) WAS RECEIVED. THE DEVICE HISTORY RECORDS WERE REVIEWED AND FOUND TO BE CONFORMING. BASED ON AN EXTENSIVE INVESTIGATION OF EVENTS REPORTED FROM SEVERAL USER FACILITIES OUTSIDE THE USA, ZIMMER IDENTIFIED THAT THE MOST PROBABLY CAUSE FOR THE OUTCOME OBSERVED WAS A LOOSE OR UNSTABLE CUP THAT RESULTED FROM USE OF SURGICAL TECHNIQUES NOT CONSISTENT WITH THE MANUFACTURER'S RECOMMENDATIONS. AS A CORRECTIVE ACTION, A RETRAINING PROGRAM FOR USERS OUTSIDE THE USA WAS INITIATED IN NOVEMBER 2009 AND REPORTED TO THE (B)(4) AS REQUIRED. THE DUROM CUP REPORTED IN THIS CASE IS NOT MARKETED IN THE USA. A SIMILAR CUP, COMPATIBLE WITH THE METASUL LDH FEMORAL HEAD, IS CLEARED IN THE USA AND A CORRECTIVE ACTION FOR THIS PRODUCT WAS REPORTED TO THE FDA IN JULY 2008 AS NOTIFICATION Z-2415/2426-2008. SINCE THIS CASE IS RELATED TO THE ISSUES FOR WHICH ZIMMER IMPLEMENTED A CORRECTIVE ACTION THERE WILL BE NO FURTHER INVESTIGATION. (B)(4).
IT WAS REPORTED THAT THE PATIENT WAS IMPLANTED A DUROM ACETABULAR COMPONENT 56/50 CODE P ON (B)(6) 2007. THE PATIENT WAS REVISED ON (B)(6) 2014 DUE TO WEAR AND OSTEOLYSIS. IN THE USER REPORT THE FOLLOWING STATEMENT WAS REPORTED: "RADIOLOGICALLY SIGNIFICANT INCREASE IN RUNNING A ROUGH OSTEOLYSIS AND BLACK CONE AT THE TRANSITION CONE / NECK ABUNDANT METAL ABRASION".
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 205724 | DUROM ACETABULAR COMPONENT 56/50 CODE P | DUROM ACETABULAR COMPONENT | KWA | ZIMMER GMBH | 2386763 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Hospitalization| R |